| A typology of preferences for participation in healthcare decision making KE Flynn, MA Smith, D Vanness Social science & medicine 63 (5), 1158-1169, 2006 | 318 | 2006 |
| Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population TM Gluecker, CD Johnson, LA Wilson, RL MacCarty, TJ Welch, ... Gastroenterology 124 (4), 911-916, 2003 | 307 | 2003 |
| Medical and surgical comanagement after elective hip and knee arthroplasty: a randomized, controlled trial JM Huddleston, KH Long, JM Naessens, D Vanness, D Larson, ... Annals of internal medicine 141 (1), 28-38, 2004 | 302 | 2004 |
| Unsuspected Extracolonic Findings at Screening CT Colonography: Clinical and Economic Impact1 PJ Pickhardt, ME Hanson, DJ Vanness, JY Lo, DH Kim, AJ Taylor, ... Radiology 249 (1), 151-159, 2008 | 224 | 2008 |
| Effects of a hospitalist model on elderly patients with hip fracture MP Phy, DJ Vanness, LJ Melton, KH Long, CD Schleck, DR Larson, ... Archives of internal medicine 165 (7), 796-801, 2005 | 222 | 2005 |
| The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis EA Pritts, DJ Vanness, JS Berek, W Parker, R Feinberg, J Feinberg, ... Gynecological surgery 12, 165-177, 2015 | 201 | 2015 |
| Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial CV Paya, JA Wilson, MJ Espy, IG Sia, MJ DeBernardi, TF Smith, R Patel, ... The Journal of infectious diseases 185 (7), 854-860, 2002 | 174 | 2002 |
| A health opportunity cost threshold for cost-effectiveness analysis in the United States DJ Vanness, J Lomas, H Ahn Annals of internal medicine 174 (1), 25-32, 2021 | 138 | 2021 |
| Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US RP Insinga, DJ Vanness, JL Feliciano, K Vandormael, S Traore, T Burke Journal of Medical Economics 21 (12), 1191-1205, 2018 | 85 | 2018 |
| Estimating (qualityadjusted) lifeyear losses associated with deaths: With application to COVID19 AH Briggs, DA Goldstein, E Kirwin, R Meacock, A Pandya, DJ Vanness, ... Health Economics 30 (3), 699-707, 2021 | 76 | 2021 |
| Some cautions on the use of instrumental variables estimators in outcomes research: how bias in instrumental variables estimators is affected by instrument strength, instrument … WH Crown, HJ Henk, DJ Vanness Value in Health 14 (8), 1078-1084, 2011 | 73 | 2011 |
| The costeffectiveness of acetaminophen, NSAIDs, and selective COX2 inhibitors in the treatment of symptomatic knee osteoarthritis CC Kamath, HM Kremers, DJ Vanness, WM O'Fallon, RL Cabanela, ... Value in Health 6 (2), 144-157, 2003 | 72 | 2003 |
| Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell … RP Insinga, DJ Vanness, JL Feliciano, K Vandormael, S Traore, ... Current medical research and opinion, 2019 | 70 | 2019 |
| Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant … EJ Bow, DJ Vanness, M Slavin, C Cordonnier, OA Cornely, DI Marks, ... BMC infectious diseases 15, 1-11, 2015 | 65 | 2015 |
| Predicting persistently high primary care use JM Naessens, MA Baird, HK Van Houten, DJ Vanness, CR Campbell The Annals of Family Medicine 3 (4), 324-330, 2005 | 59 | 2005 |
| Investing in the disadvantaged: Assessing the benefits and costs of social policies M Stegman, B Wolfe, N Tefft, CR Belfield, DJ Vanness, MS Salzer, ... Georgetown University Press, 2009 | 58 | 2009 |
| Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using … M Bounthavong, A Zargarzadeh, DI Hsu, DJ Vanness Value in Health 14 (5), 631-639, 2011 | 55 | 2011 |
| Factors influencing clinical decisions to initiate thyroxine therapy for patients with mildly increased serum thyrotropin (5.1-10.0 mIU/L) V Fatourechi, M Lankarani, PG Schryver, DJ Vanness, KH Long, GG Klee Mayo Clinic Proceedings 78 (5), 554-560, 2003 | 52 | 2003 |
| A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses J Levy, M Rosenberg, D Vanness Value in Health 21 (6), 677-684, 2018 | 51 | 2018 |
| Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance CJ Balentine, DJ Vanness, DF Schneider Surgery 163 (1), 88-96, 2018 | 48 | 2018 |
Wael SaberMedical College of Wisconsin在 mcw.edu 的电子邮件经过验证
